bromo-deaza-SAH   Click here for help

GtoPdb Ligand ID: 7018

PDB Ligand
Compound class: Synthetic organic
Comment: Bromo-deaza-SAH is a small molecule inhibitor of the chromatin modifying enzymes DOT1-like histone H3K79 methyltransferase (DOT1L) and DNA (cytosine-5-)-methyltransferase 1 (DNMT1).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 5
Rotatable bonds 7
Topological polar surface area 195.04
Molecular weight 461.04
XLogP -1.65
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES OC(=O)C(CCSCC1OC(C(C1O)O)n1cc(c2c1ncnc2N)Br)N
Isomeric SMILES OC(=O)[C@H](CCSC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cc(c2c1ncnc2N)Br)N
InChI InChI=1S/C15H20BrN5O5S/c16-6-3-21(13-9(6)12(18)19-5-20-13)14-11(23)10(22)8(26-14)4-27-2-1-7(17)15(24)25/h3,5,7-8,10-11,14,22-23H,1-2,4,17H2,(H,24,25)(H2,18,19,20)/t7-,8+,10+,11+,14+/m0/s1
1. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L et al.. (2011)
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.
Cancer Cell, 20 (1): 66-78. [PMID:21741597]
2. Muntean AG, Hess JL. (2012)
The pathogenesis of mixed-lineage leukemia.
Annu Rev Pathol, 7: 283-301. [PMID:22017583]
3. Nguyen AT, Taranova O, He J, Zhang Y. (2011)
DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
Blood, 117 (25): 6912-22. [PMID:21521783]
4. Yu W, Smil D, Li F, Tempel W, Fedorov O, Nguyen KT, Bolshan Y, Al-Awar R, Knapp S, Arrowsmith CH et al.. (2013)
Bromo-deaza-SAH: a potent and selective DOT1L inhibitor.
Bioorg Med Chem, 21 (7): 1787-94. [PMID:23433670]